The World Health Organization published an announcement introducing guidance on evidence generation for new TB diagnostics. Short statement. Clear purpose: to provide a framework for evidence generation. The source presented the guidance as a resource for those involved in developing and evaluating diagnostic tests. The WHO item did not include the full guidance text within the announcement.
The release identified primary audiences in broad terms: test developers, regulatory authorities and national tuberculosis programmes. The wording in the source indicated the guidance is meant to clarify what types of evidence stakeholders should produce when developing and seeking introduction of new diagnostics. The source did not, however, list specific stakeholder roles, nor did it present concrete operational responsibilities for each group.
The announcement did not specify study designs, primary or secondary endpoints, or statistical benchmarks that developers should meet. The source omitted details on recommended sample sizes, enrollment strategies, comparator standards, or whether prospective clinical evaluations were required. Any request for trial-level criteria—such as diagnostic accuracy thresholds, clinical impact measures, or implementation outcomes—was not described in the text provided by WHO.
The source also did not indicate whether the guidance includes templates, case report forms, or standard operating procedures for performance evaluations. In short: the WHO release stated the existence and intent of guidance but did not publish methodological appendices within the announcement.
The WHO announcement framed the guidance as relevant to regulators but stopped short of detailing how national regulatory bodies should use it. The source did not describe pathways for regulatory acceptance, harmonization across jurisdictions, or whether WHO prequalification or endorsement processes would be tied to the evidence described. The guidance’s relationship to regulatory approval timelines and post-market surveillance requirements was not set out in the announcement.
Implementation at country level was mentioned only at a high level. The source did not provide an implementation roadmap, funding sources for rollout, or technical assistance commitments. There were no country case examples, pilot rollouts or timelines included in the WHO item.
For test developers, the guidance—per the source—aims to clarify expectations around evidence generation so that new products can be assessed consistently. Short sentence. For regulators, the release suggests the guidance could inform national decisions on adoption and approval. The announcement implied national programmes might use the guidance when planning introduction and scale-up.
What the source did report: the guidance exists and is positioned as a shared reference for multiple stakeholders. What the source did not report: concrete operational steps, obligations for manufacturers, or how adoption would be monitored. The announcement left these elements undefined.
The WHO item left several specific questions unanswered. The source did not provide the guidance document in full within the announcement. It did not list methodological standards, nor did it specify how the guidance differentiates among assay types (for example, molecular versus antigen tests) or patient groups (children versus adults). The announcement did not identify collaborators, funders, or technical working groups involved in drafting the guidance.
The lack of detail in the public announcement limits immediate operational use. Investigators, manufacturers and national policy teams will need to consult the full guidance document to apply recommendations. The source did not indicate when or where that document could be accessed in full, or whether companion materials—such as templates or training modules—would follow.
This article ends on the concrete gaps reported in the WHO announcement: methodological specifications, regulatory pathways, implementation timelines and supporting materials were not included in the source. Those remain open questions until the full guidance or supplementary documentation is published by WHO.